Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Talia Diker-Cohen"'
Autor:
Daniel Shepshelovich, A Zer, Talia Diker-Cohen, Ran D. Balicer, Noam Barda, Hadar Goldvaser, Noa Dagan, Anat Gafter-Gvili
Publikováno v:
QJM: An International Journal of Medicine. 115:287-291
Summary Background Pneumonia is more common in smokers compared with non-smokers. A high 1-year prevalence of lung cancer following hospitalization for pneumonia was demonstrated in heavy smokers. Aim To assess the association between hospitalization
Publikováno v:
Osteoporosis International. 32:413-424
The immunomodulatory effects of denosumab have raised concerns for risk of malignancy. This meta-analysis of 25 randomized controlled trials (21,523 patients) shows similar risk of malignancy between denosumab (60 mg every 6 months, up to 48 months)
Autor:
Talia Diker-Cohen, Eyal Robenshtok, Hiba Masri-Iraqi, Dania Hirsch, Hadar Duskin-Bitan, Ilan Shimon, Ilana Slutzky-Shraga, Alexander Gorshtein, Joelle Singer, Gloria Tsvetov, Nina Nemirovsky
Publikováno v:
Maturitas. 135:47-52
With the current aging of the world's population, primary hyperparathyroidism (PHPT) is increasingly detected in the elderly. Yet data on the presentation and outcome of PHPT in this group are scarce. The objective was to describe a cohort of patient
Autor:
Aviram Mizrachi, Talia Diker-Cohen, Amit Ritter, Gideon Bachar, Hadar Duskin-Bitan, Igor Vainer, Ilan Shimon, Dania Hirsch, Eyal Robenshtok
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 105:e2145-e2151
Background The use of thyroglobulin (Tg) and thyroglobulin antibodies (TgAb) for detecting disease recurrence is well validated following total thyroidectomy and radioiodine ablation. However, limited data are available for patients treated with thyr
Autor:
Daniel Shepshelovich, Anat Gafter-Gvili, Gloria Tsvetov, Dana Rosenberg, Tomer Avni, Talia Diker-Cohen
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 105:1641-1658
Context Denosumab inhibits the receptor activator of nuclear factor κ-Β ligand, an immune system modulator. Safety endpoints including risk for infections were assessed as secondary outcomes in randomized controlled trials (RCTs) of the drug. Objec
Publikováno v:
Osteoporosis International. 31:655-665
Hypocalcemia was reported at low rates (0.05–1.7%) in denosumab-treated postmenopausal women with osteoporosis. This real-life study shows a 7.4% rate of denosumab-induced hypocalcemia in community-dwelling osteoporotic men and women. Pretreatment
Autor:
Amit Akirov, Talia Diker-Cohen, Alexander Gorshtein, Tzipora Shochat, Ilan Shimon, Idit Dotan
Publikováno v:
Surgery. 166:184-192
Background Glucose variability is common among hospitalized patients, but the prognostic implications among patients hospitalized in surgical wards are unknown. The objective of this study was to investigate the association between glucose variabilit
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Endocrine Abstracts.
Autor:
Daniel Shepshelovich, Dana Rosenberg, Talia Diker-Cohen, Anat Gafter-Gvili, Tomer Avni, Gloria Tsvetov
Publikováno v:
The Journal of clinical endocrinology and metabolism. 106(1)